Jump to content
Sclero Forums

Search the Community

Showing results for tags 'clinical trials'.



More search options

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Forums

  • Worldwide
    • Welcome: Guidelines and FAQs
    • Sclero Forums (MAIN)
    • UK Scleroderma
    • News
    • Personal Support

Blogs

  • CFM Babs from Chorley FM
  • barefut impressions
  • My Two Cents...
  • Amanda Thorpe's Blog
  • Joelf's Blog
  • Michael Thorpe's Blog

Find results in...

Find results that contain...


Date Created

  • Start

    End


Last Updated

  • Start

    End


Filter by number of...

Joined

  • Start

    End


Group


Location

Found 33 results

  1. Fibrocell’s FX-013 Therapy Wins FDA Rare Pediatric Disease Designation for Localized Scleroderma. The U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to FX-013, a Fibrocell gene therapy candidate to treat children with moderate to severe localized scleroderma. Scleroderma News, 06/13/2017. (Also see Clinical Trials and Juvenile Scleroderma Research) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  2. CATALYST – for patients with CTD-PAH. CATALYST is a Phase III clinical study evaluating the safety and efficacy of bardoxolone methyl (an oral medication) for the treatment of pulmonary arterial hypertension associated with connective tissue disease (CTD-PAH). Approximately 200 patients will be enrolled at centres in various countries around the world. Reata Pharmaceuticals, Inc., 06/29/2017. (Also see Clinical Trials) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  3. Cytori Logs Final 48 Week Patient Follow Up Visit in Scleroderma Trial. Cytori Therapeutics, Inc. today announced that it has now completed all 48 week follow up monitoring visits in its U.S. FDA approved Phase III STAR trial. A total of 88 subjects were enrolled and the last subject’s 48 week visit was conducted earlier this week. Globe Newswire, 05/23/2017. (Also see Scleroderma Clinical Trials) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  4. Expanded Access Programs. A Expanded Access Program (EAP) allows physicians and patients access to much needed medicines when there are no other viable options left. These may be investigational therapies as well as drugs not available in the patients' country and the ultimate intention is to treat unmet clinical need. WEP Clinical. (Also see Clinical Trials and Medication Programs) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  5. Corbus to Present Promising Data on Resunab as Systemic Sclerosis Treatment. Corbus Pharmaceuticals will present results showing that Resunab (JBT-101) can trigger specific molecular pathways which resolve inflammation and halt fibrosis. Scleroderma News, 03/07/2017. (Also see Clinical Trials) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  6. Multiplex serum protein analysis reveals potential mechanisms and markers of response to hyperimmune caprine serum (HICS) in systemic sclerosis. Our results suggest mechanisms of action for HICS, including upregulation of α-MSH, that has been shown to be anti–fibrotic in preclinical models, and possible markers to be included in future trials targeting skin in diffuse cutaneous systemic sclerosis. PubMed, Arthritis Res Ther, 2017 Mar 7;19(1):45. (Also see Clinical Trials) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  7. Improved cough and cougho–specific quality of life in patients treated for sclerodermao–related interstitial lung disease (SSc–ILD): Results of Scleroderma Lung Study II. Frequent cough occurs commonly in SSc–ILD and might serve as a useful surrogate marker of treatment response in SSc–ILD trials. PubMed, Chest, 12/22/2016. (Also see Clinical Trials) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  8. Systemic sclerosis : What is currently available for treatment? Therapy options in systemic sclerosis have changed over the past 10 years and this trend will also continue in the future. PubMed, Internist (Berl), 2016 Dec;57(12):1155-1163. (Also see Scleroderma Clinical Trials) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
×
×
  • Create New...